manidipine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| calcium channel blockers, nifedipine derivatives | 1631 | 89226-50-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 10 | mg | O |
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyponatraemia | 62.09 | 33.63 | 27 | 463 | 101305 | 46584267 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug interaction | 61.59 | 35.59 | 47 | 756 | 199521 | 29752154 |
| Dermatitis bullous | 44.14 | 35.59 | 13 | 790 | 6091 | 29945584 |
| Acute kidney injury | 42.99 | 35.59 | 44 | 759 | 273798 | 29677877 |
| Hyponatraemia | 37.66 | 35.59 | 23 | 780 | 67179 | 29884496 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C08CA11 | CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives |
| ATC | C09BB12 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, COMBINATIONS ACE inhibitors and calcium channel blockers |
| MeSH PA | D000959 | Antihypertensive Agents |
| MeSH PA | D002121 | Calcium Channel Blockers |
| MeSH PA | D000077264 | Calcium-Regulating Hormones and Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D049990 | Membrane Transport Modulators |
Drug Use (View source of the data)
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.7 | Basic |
| pKa2 | 2.87 | Basic |
| pKa3 | 2.2 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Voltage-gated L-type calcium channel | Ion channel | BLOCKER | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||||
| Cruzipain | Enzyme | IC50 | 5.22 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D01553 | KEGG_DRUG |
| 89226-75-5 | SECONDARY_CAS_RN |
| C0065656 | UMLSCUI |
| CHEBI:135849 | CHEBI |
| CHEMBL1085699 | ChEMBL_ID |
| DB09238 | DRUGBANK_ID |
| C054218 | MESH_SUPPLEMENTAL_RECORD_UI |
| 6300 | INN_ID |
| 6O4754US88 | UNII |
| 4008 | PUBCHEM_CID |
| 259487 | RXNORM |
| 008164 | NDDF |
| 008165 | NDDF |
| 765322004 | SNOMEDCT_US |
| 765323009 | SNOMEDCT_US |
Pharmaceutical products:
None